Literature DB >> 27052531

Supplementation with Folic Acid, but Not Creatine, Increases Plasma Betaine, Decreases Plasma Dimethylglycine, and Prevents a Decrease in Plasma Choline in Arsenic-Exposed Bangladeshi Adults.

Megan N Hall1, Caitlin G Howe2, Xinhua Liu3, Marie A Caudill4, Olga Malysheva4, Vesna Ilievski2, Angela M Lomax-Luu2, Faruque Parvez2, Abu B Siddique5, Hasan Shahriar5, Mohammad N Uddin5, Tariqul Islam5, Joseph H Graziano2, Mary V Gamble2.   

Abstract

BACKGROUND: Folic acid (FA) supplementation facilitates urinary excretion of arsenic, a human carcinogen. A better understanding of interactions between one-carbon metabolism intermediates may improve the ability to design nutrition interventions that further facilitate arsenic excretion.
OBJECTIVE: The objective was to determine if FA and/or creatine supplementation increase choline and betaine and decrease dimethylglycine (DMG).
METHODS: We conducted a secondary analysis of the Folic Acid and Creatine Trial, a randomized trial in arsenic-exposed Bangladeshi adults (n = 605, aged 24-55 y, 50.3% male) who received arsenic-removal water filters. We examined treatment effects of FA and/or creatine supplementation on plasma choline, betaine, and DMG concentrations, measured by LC-tandem mass spectrometry at baseline and at week 12. Group comparisons were between 1) 400 and 800 μg FA/d (FA400 and FA800, respectively) compared with placebo, 2) creatine (3 g/d) compared with placebo, and 3) creatine plus FA400 compared with FA400.
RESULTS: Choline decreased in the placebo group (-6.6%; 95% CI: -10.2%, -2.9%) but did not change in the FA groups (FA400: 2.5%; 95% CI: -0.9%, 6.1%; FA800: 1.4%; 95% CI: -2.5%, 5.5%; P < 0.05). Betaine did not change in the placebo group (-3.5%; 95% CI: -9.3%, 2.6%) but increased in the FA groups (FA400: 14.1%; 95% CI: 9.4%, 19.0%; FA800: 13.0%; 95% CI: 7.2%, 19.1%; P < 0.01). The decrease in DMG was greater in the FA groups (FA400: -26.7%; 95% CI: -30.9%, -22.2%; FA800: -27.8%; 95% CI: -31.8%, -23.4%) than in the placebo group (-12.3%; 95% CI: -18.1%, -6.2%; P < 0.01). The percentage change in choline, betaine, and DMG did not differ between creatine treatment arms and their respective reference groups.
CONCLUSION: Supplementation for 12 wk with FA, but not creatine, increases plasma betaine, decreases plasma DMG, and prevents a decrease in plasma choline in arsenic-exposed Bangladeshi adults. This trial was registered at clinicaltrials.gov as NCT01050556.
© 2016 American Society for Nutrition.

Entities:  

Keywords:  arsenic; betaine; choline; creatine; folic acid

Mesh:

Substances:

Year:  2016        PMID: 27052531      PMCID: PMC4841924          DOI: 10.3945/jn.115.227132

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  37 in total

Review 1.  Phospholipid biosynthesis in mammalian cells.

Authors:  Jean E Vance; Dennis E Vance
Journal:  Biochem Cell Biol       Date:  2004-02       Impact factor: 3.626

2.  Methionine metabolism in mammals. Adaptation to methionine excess.

Authors:  J D Finkelstein; J J Martin
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

Review 3.  Creatine: biosynthesis, regulation, and function.

Authors:  J B Walker
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1979

4.  Labile methyl group balances in the human: the role of sarcosine.

Authors:  S H Mudd; M H Ebert; C R Scriver
Journal:  Metabolism       Date:  1980-08       Impact factor: 8.694

Review 5.  Creatine and creatinine metabolism.

Authors:  M Wyss; R Kaddurah-Daouk
Journal:  Physiol Rev       Date:  2000-07       Impact factor: 37.312

6.  Labile methyl balances for normal humans on various dietary regimens.

Authors:  S H Mudd; J R Poole
Journal:  Metabolism       Date:  1975-06       Impact factor: 8.694

7.  Determination of choline, betaine, and dimethylglycine in plasma by a high-throughput method based on normal-phase chromatography-tandem mass spectrometry.

Authors:  Pål I Holm; Per Magne Ueland; Gry Kvalheim; Ernst A Lien
Journal:  Clin Chem       Date:  2003-02       Impact factor: 8.327

8.  Toxicogenomic analysis of aberrant gene expression in liver tumors and nontumorous livers of adult mice exposed in utero to inorganic arsenic.

Authors:  Jie Liu; Yaxiong Xie; Jerrold M Ward; Bhalchandra A Diwan; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2003-12-22       Impact factor: 4.849

9.  Effects of dietary folate intake and folate binding protein-1 (Folbp1) on urinary speciation of sodium arsenate in mice.

Authors:  Ofer Spiegelstein; Xiufen Lu; X Chris Le; Aron Troen; Jacob Selhub; Stepan Melnyk; S Jill James; Richard H Finnell
Journal:  Toxicol Lett       Date:  2003-11-30       Impact factor: 4.372

10.  Folic Acid and Creatine as Therapeutic Approaches to Lower Blood Arsenic: A Randomized Controlled Trial.

Authors:  Brandilyn A Peters; Megan N Hall; Xinhua Liu; Faruque Parvez; Tiffany R Sanchez; Alexander van Geen; Jacob L Mey; Abu B Siddique; Hasan Shahriar; Mohammad Nasir Uddin; Tariqul Islam; Olgica Balac; Vesna Ilievski; Pam Factor-Litvak; Joseph H Graziano; Mary V Gamble
Journal:  Environ Health Perspect       Date:  2015-05-15       Impact factor: 9.031

View more
  8 in total

Review 1.  State of the science review of the health effects of inorganic arsenic: Perspectives for future research.

Authors:  Paul B Tchounwou; Clement G Yedjou; Udensi K Udensi; Maricica Pacurari; Jacqueline J Stevens; Anita K Patlolla; Felicite Noubissi; Sanjay Kumar
Journal:  Environ Toxicol       Date:  2018-12-04       Impact factor: 4.119

2.  Targeted metabolomics to understand the association between arsenic metabolism and diabetes-related outcomes: Preliminary evidence from the Strong Heart Family Study.

Authors:  Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Teodoro Bottiglieri; Mary V Gamble; Shelley A Cole; Jinying Zhao; Ana Navas-Acien
Journal:  Environ Res       Date:  2018-09-27       Impact factor: 6.498

Review 3.  Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults.

Authors:  Sajin Bae; Elena Kamynina; Heather M Guetterman; Adetutu F Farinola; Marie A Caudill; Robert J Berry; Patricia A Cassano; Patrick J Stover
Journal:  Cochrane Database Syst Rev       Date:  2021-10-18

4.  Trimethylamine-N-oxide and its biological variations in vegetarians.

Authors:  Rima Obeid; Hussain M Awwad; Markus Keller; Juergen Geisel
Journal:  Eur J Nutr       Date:  2016-08-25       Impact factor: 5.614

5.  Association between body mass index and arsenic methylation in three studies of Bangladeshi adults and adolescents.

Authors:  Ahlam Abuawad; Miranda J Spratlen; Faruque Parvez; Vesna Slavkovich; Vesna Ilievski; Angela M Lomax-Luu; Roheeni Saxena; Hasan Shahriar; Mohammad Nasir Uddin; Tariqul Islam; Joseph H Graziano; Ana Navas-Acien; Mary V Gamble
Journal:  Environ Int       Date:  2021-02-04       Impact factor: 9.621

6.  A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia.

Authors:  Philip T James; Ousubie Jawla; Nuredin I Mohammed; Kabiru Ceesay; Fatai M Akemokwe; Bakary Sonko; Ebrima A Sise; Andrew M Prentice; Matt J Silver
Journal:  PLoS Med       Date:  2019-08-13       Impact factor: 11.069

Review 7.  Prenatal Environmental Metal Exposure and Preterm Birth: A Scoping Review.

Authors:  Rasheda Khanam; Ishaan Kumar; Opeyemi Oladapo-Shittu; Claire Twose; Asmd Ashraful Islam; Shyam S Biswal; Rubhana Raqib; Abdullah H Baqui
Journal:  Int J Environ Res Public Health       Date:  2021-01-12       Impact factor: 3.390

8.  Betaine and choline status modify the effects of folic acid and creatine supplementation on arsenic methylation in a randomized controlled trial of Bangladeshi adults.

Authors:  Anne K Bozack; Caitlin G Howe; Megan N Hall; Xinhua Liu; Vesna Slavkovich; Vesna Ilievski; Angela M Lomax-Luu; Faruque Parvez; Abu B Siddique; Hasan Shahriar; Mohammad N Uddin; Tariqul Islam; Joseph H Graziano; Mary V Gamble
Journal:  Eur J Nutr       Date:  2020-09-11       Impact factor: 4.865

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.